British Medical Journal publishes letter calling on government to reduce rate of antidepressant prescribing
December 5, 2023Medical Communications British Medical Journal, Neurology, antidepressants, over-prescribing
A group of medical professionals and politicians have published an open letter in the British Medical Journal which calls on …
Genentech shares positive results from phase 3 trial for breast cancer treatment
December 5, 2023Research and Development Genentech, Oncology, breast cancer, oncology
Genentech, a member of the Roche Group, has announced positive results from the phase 3 INAVO120 study, which assessed the …
Dr Stefano Gulià appointed as chief scientific officer of Kling Bio
December 5, 2023Business Services Kling Bio, Oncology, appointment, chief scientific officer
Kling Bio has announced the appointment of Dr Stefano Gulià as chief scientific officer. Dr Gulià has over 15 years …
Roche to acquire Carmot Therapeutics for $2.7bn
December 4, 2023Business Services Obesity, Roche, acquisition, diabetes
Roche has announced that it has entered into a definitive merger agreement with Carmot Therapeutics, in which it will acquire …
Eli Lilly’s Jaypirca approved in US for leukaemia and lymphoma treatment
December 4, 2023Medical Communications Eli Lilly, FDA, Jaypirca, Oncology, leukaemia, lymphoma
Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved Jaypirca (pirtobrutinib, 100mg and 50mg tablets) …
GSK shares data from global shingles survey
December 1, 2023Medical Communications GSK, Infections and infestations, data, shingles
GSK has announced data from its new global survey about shingles. The data suggests that there are some significant gaps …
AbbVie to acquire ImmunoGen for approximately $10.1bn
December 1, 2023Sales and Marketing AbbVie, Oncology, acquisition
AbbVie and ImmunoGen have announced that AbbVie will acquire ImmunoGen and its lead cancer therapy Elahere (mirvetuximab soratansine-gynx), a first …
FDA accepts NDA for Karuna’s schizophrenia treatment
November 30, 2023Medical Communications FDA, Karuna Therapeutics, NDA, Neurology, schizophrenia
Karuna Therapeutics has announced that the US Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for …
Vivos Therapeutics gains FDA 510(k) clearance for sleep apnea treatment device
November 30, 2023Medical Communications Devices, FDA, Vivos Therapeutics, sleep apnea
Vivos Therapeutics has announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for the …
Tolremo doses first patient in phase 1 trial for drug to combat transcriptional cancer drug resistance
November 29, 2023Research and Development Oncology, Tolremo, clinical trial, drug resistance, solid tumours
Tolremo Therapeutics has announced that it has dosed the first patient in its first-in-human clinical trial to assess the safety, …
FDA grants breakthrough device designation to Inflammatix’s TriVerity Acute Infection and Sepsis Test System
November 29, 2023Research and Development FDA, Infections and infestations, Inflammatix, TriVerity, infection, sepsis
Inflammatix has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Device Designation to the company’s lead …
FDA accepts new drug application for Orexo’s opioid overdose medication
November 28, 2023Research and Development FDA, Opioid overdose, Pharmacy, opioids, orexo
Orexo has announced that its New Drug Application (NDA) for OX124 has been accepted for review by the US Food …
Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment
November 28, 2023Research and Development Arcturus Therapeutics, Chronic Diseases, FDA, ODD, cystic fibrosis
Arcturus Therapeutics has announced that the US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to ARCT-032, …
Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment
November 27, 2023Medical Communications COPD, Cardiology, Dupixent, Sanofi, clinical trial
Sanofi and Regeneron have announced results from the second investigational phase 3 NOTUS trial for Dupixent as a treatment for …
GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment
November 27, 2023Medical Communications Blenrep, GSK, Oncology, clinical trial, multiple myeloma
GSK has announced positive results from a planned interim efficacy analysis of the phase 3 DREAMM-7 head-to-head trial which assessed …
Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment
November 24, 2023Research and Development Alladapt Immunotherapeutics, Allergic Disorders, FDA, fast track designation, food allergy
Alladapt Immunotherapeutics has announced that ADP101 has received Fast Track Designation from the US Food and Drug Administration (FDA) as …
Syncona to acquire Freeline Therapeutics for $28.3m
November 24, 2023Business Services Freeline Therapeutics, Pharmacy, acquisition, syncona
Freeline Therapeutics has announced that it has entered into a definitive agreement with newly established portfolio company Syncona, in which …
Landos Biophama shares results from phase 1b trial for ulcerative colitis treatment
November 23, 2023Medical Communications Gastrointestinal tract, Landos Biopharma, clinical trial, ulcerative colitis
Landos Biopharma has announced that it has shared safety, tolerability, pharmacokinetics and clinical efficacy results for the NX-13 phase 1b …
MorphoSys shares phase 3 trial results for pelabresib in myelofibrosis treatment
November 23, 2023Research and Development Haematology, clinical trial, morphosys, myelofibrosis, pelabresib
MorphoSys has announced topline results from its phase 3 MANIFEST-2 study, which assessed pelabresib, an investigational BET inhibitor, in combination …
Genentech and NVIDIA enter AI research collaboration
November 22, 2023Research and Development AI, Genentech, Pharmacy, research collaboration
Genentech has announced that it has entered into a multi-year strategic research collaboration with NVIDIA that is intended to pair …
Latest content
MHRA approves Romvimza for tenosynovial giant cell tumour
Panthera opens clinical trial site at Keele University
Santen joins inaugural Global Summit for Eye Health as partner
